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Introduction: Cardiac remodelling is one of the pathogenic pathways 
leading to heart failure, which occurs due to ischemic, mechanical and 
inflammatory damage to cardio myocytes and cardiac interstitium. 
Purpose: Detection of biochemical markers of cardiac 
remodeling in the context of ischemic myocardial 
injury.
Material and methods: Have been analysed 82 bibliographic sources 
published during the 2000-2019 in the electronic databases Medline, 
PubMed, Medscape, Hinari and Google Academic, as well as from the 
Medical Scientific Library of “Nicolae Testemitanu” State University of 
Medicine and Pharmacy.
Results:The possible mechanisms by which galectin‐3 mediates cardiac 
fibrosis have been explored by a number of groups (Figure 1). Direct 
evidence has shown that recombinant galectin‐3 can convert silent 
fibroblasts into myofibroblasts and induce cardiac fibroblast 
proliferation, TGF‐β synthesis, collagen production.Was demonstrated 
that increasing galectin‐3 protein expression by the galectin‐3 gene 
promotes collagen I synthesis in HL‐I cardiomyocytes, which promotes 
cardiac decompensation.Others studies revealed that galectin‐3 can 
promote oxidative stress in human cardiac fibroblasts, a novel 
mechanism of galectin‐3‐induced cardiac damage. Oxidative stress is a 
disturbance in the balance between reactive oxygen species (ROS) 
production and antioxidant detoxification. In patients with HF, oxidative 
stress occurs in the myocardium and correlates with left ventricular 
dysfunction.
Conclusions: Accumulating studies demonstrate that galectin‐3 is 
upregulated in clinical and experimental HF and plays an important role 
in the pathogenesis of cardiac fibrosis. Inhibition of galectin‐3 activation 
after heart injury may provide an alternative therapeutic approach in the 
prevention and treatment of HF. 
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